NASHVILLE (AP) — Vanderbilt University officials say earnings from technology commercialization has more than quadrupled in the past three years, bringing in more than $24.5 million in the 2013 fiscal year.

The Tennessean reported (http://tnne.ws/GWqyNp) that the earnings growth reflects the university's renewed focus on turning research into commercialized products.

The school has reached licensing agreements in the past year with Bristol-Myers Squibb to develop new drugs for Parkinson's disease and AstraZeneca to develop drugs for schizophrenia and Alzheimer's disease. The university also partnered with Parker Hannifin Corp. to commercialize a lightweight, mechanical exoskeleton technology.